Search results
Guidance below summarizes basic storage, preparation, scheduling, administration, and dosage for all 2024–25 Pfizer-BioNTech COVID-19 vaccine products.
3 wrz 2024 · Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) for individuals 6 months through 11 years of age; The following COVID-19 vaccines are approved by FDA: Comirnaty (2024-2025 Formula)
25 cze 2022 · COMIRNATY® (COVID-19 Vaccine, mRNA) is a vaccine approved for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. COMIRNATY® is administered as a 2-dose primary series.
22 sie 2024 · Individuals 5 years through 11 years of age regardless of previous vaccination are eligible to receive a single dose of the updated, authorized Moderna or Pfizer-BioNTech COVID-19 vaccines;...
20 wrz 2024 · Upon authorization by the European Commission (EC), the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted COVID-19 vaccine generates a substantially improved response against multiple circulating Omicron JN.1 sublineages as did the Omicron JN.1-adapted COVID-19 vaccine authorized by the European ...
11 gru 2020 · Indication & Authorized Use. COMIRNATY ® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech. It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older. It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:
11 wrz 2023 · The first dose of Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) is administered three weeks after receipt of the previous dose and the second dose is administered at least 8...
